Abstract: The present invention discloses a therapeutic gas release system for oral administration comprising a therapeutic gas releasing compound A, and a therapeutic gas release triggering compound B, wherein compound A and B are separated from each other by an inner septum during storage of the system, wherein compound A and B are surrounded by an outer membrane, which is a gas-permeable and water- and solid-impermeable membrane, preferably a silicone membrane, and wherein therapeutic gas release from the system is activated before oral administration by breaking the inner septum. The therapeutic gas released from the system of the present invention is suitable for the treatment of (inflammatory) diseases of the gastrointestinal tract.

Abstract: A system for one-sided measuring a presence of magnetic particles in a probe volume comprises a one-sided coil assembly and a current controller, wherein the one-sided coil assembly is arranged around a central coil assembly axis for generating a rotating magnetic field distribution and comprises at least 3, preferably at least 4, circumferentially distributed coil assembly sectors, wherein the current controller is configured to generate a time varying current in each of said coil assembly sectors, said time varying current comprising a periodic modulation with a rotation frequency and phase shifted between adjacent coil assembly sectors to generate a magnetic field rotating in a plane perpendicular to the coil assembly axis, said magnetic field rotating with a rotation frequency associated with a frequency of said periodic modulation, and wherein the system is configured for measuring said presence of magnetic particles in said probe volume with said one-sided coil assembly.

Abstract: The present invention relates to novel monoclonal anti-human-GDF-15 antibodies, pharmaceutical compositions, kits, methods and uses and the cell lines capable of producing the monoclonal antibodies described herein. The present invention further relates to novel antibodies to human GDF-15 capable of inhibiting cancer growth.

Abstract: The present invention concerns a silane of formula (1) R1aSIR4-a??(1) where the group R1 or each of the groups R1 independently is bound to the silicon via an oxygen atom, comprises a straight or branched hydrocarbonaceous chain having one or more elements, wherein (a) each of the elements has not more than 8 consecutive carbon atoms, each of plural elements of the hydrocarbonaceous chain being separated from the next element by a cleavable group and/or (b) the elements have one or more cleavable groups and any hydrocarbonaceous chains remaining upon cleavage of said group(s) are water soluble, wherein said cleavable groups are selected from ester, anhydride, amide, carbonate, carbamate, ketal, acetal, disulfide, imine, hydrazone and oxime groups, has at least one thiol or a primary or secondary amino group, the group R or each of the groups R is independently a hydrolytically condensable group, and a is 1,2,3 or 4.

Abstract: The present invention relates to monoclonal anti-human-GDF-15 antibodies. The antibodies include chimeric antibodies and humanized antibodies. The invention also relates to monoclonal anti-human-GDF-15 antibodies including murine anti bodies, chimeric antibodies and humanized antibodies for use in methods for the treatment of cancer cachexia and also for the treatment of cancer. The invention also provides pharmaceutical compositions, kits, methods and uses and cell lines capable of producing the monoclonal antibodies of the invention.

Abstract: The present invention discloses a therapeutic system for the topic, transdermal and transcutaneous application of carbon monoxide (CO), comprising: (i) an adhesive layer, (ii) a gas-permeable and liquid- and solid-impermeable membrane, (iii) a reaction chamber comprising a CO releasing molecule A, and (iv) a gas-impermeable backing layer, wherein the transdermal therapeutic system is configured that the CO releasing molecule A can be brought into contact with a CO release triggering compound B in the reaction chamber (iii). The therapeutic system can be used for the treatment of wounds, inflammatory diseases of the skin, and inflammatory diseases of subcutaneous skin tissue, joints and tendons.

Abstract: The present invention relates to compounds comprising denatonium linked to the C-terminus of a protease-sensitive peptide; or a salt thereof. The compounds are useful in the diagnosis of inflammatory conditions of the oral cavity.

Abstract: The invention relates to a CD84 inhibitor for use in treating or preventing of an ischemic disease and/or ischemic tissue damage, the use of a CD84 inhibitor for inhibiting CD84 mediated T cell migration in vitro and a method for screening for a CD84 inhibitor.

Abstract: The present invention relates to a set of polypeptides and its uses. In particular, the present invention relates to a set of polypeptides whereby this set comprises two polypeptides each of which comprises a targeting moiety “T” binding to an antigen “A” and a fragment of “F” of a functional domain, wherein said two polypeptides are not associated with each other in absence of a substrate that has “A” at (on) its surface and wherein, upon dimerization of “F”, the resulting dimer becomes functional. Furthermore, medical and diagnostic uses of said set are described. Moreover, the present invention relates to nucleic acid molecule(s) encoding said set of polypeptides. The present invention also relates to a vector comprising the nucleotide sequence of nucleic acid molecule(s) encoding said set of polypeptides. Furthermore, the present invention relates to pharmaceutical compositions comprising said set of polypeptides. Moreover, the present invention relates to a kit comprising said set of polypeptides.

Abstract: The present invention relates to uses of inhibitors of human Growth and Differentiation Factor 15 (GDF-15), and to combined uses of such inhibitors with immune checkpoint blockers, in the treatment of solid cancers.

Abstract: An apparatus for determining a disease parameter describing a type of cardiac disease includes a unit for reading input parameters representing 3D myocardial velocity fields with voxel wise 3D velocity information. The velocity vectors represent velocity of a voxel of a region of the heart at a predefined time point or time interval; a velocity vector depicts a voxel wise 3D velocity of the myocardium with different magnitude. A processor applies an algorithm to obtain a rotation parameter and/or strain-rate-tensor representing local curl of the input parameters and local rate of strain at a certain spatial point, at a certain time point or time interval. A processor calculates the disease parameter on the basis of the rotation parameter and strain-rate-tensor, dividing an absolute value of the rotation parameter by an eigenvalue. The disease parameter reflects a proportion to overall deformation of local layer shearing with regard to local pure deformation.

Abstract: The present invention relates to a new class of sucrose esters and a method for their preparation.

Abstract: A system for generating a traveling field free line, traveling along a propagation direction different from the orientation of said traveling field free line, said system comprising at least a first and a second coil assembly, wherein said first coil assembly is configured for generating a first stationary field free line at a first location when a current is flowing in the first coil assembly and the second coil assembly is current free, and wherein said second coil assembly is configured for generating a second stationary field free line at a second location, when a current is flowing in the second coil assembly and the first coil assembly is current free. The system further comprises a controller configured for driving the first and second coil assemblies with corresponding driving currents synchronized with each other, such that said traveling field free line travels along the propagation direction from a first location towards a second location.

Abstract: The present invention relates to a device for the photocatalytic reduction of a substance with a structured reaction plate and/or a structured housing, wherein the reaction plate has, at least in some regions, a surface which contains a material with negative electron affinity and which can be electronically excited with radiation having a wavelength of ?180 nm.

Abstract: A new class of sucrose esters and a method for their preparation is described herein.

Abstract: The Sleeping Beauty (SB) transposon is an efficient non-viral tool for inserting transgenes into cells. Its broad utilization in gene therapy has been hampered by uncontrolled transposase gene activity and the inability to use transposase protein directly. The present invention concerns the finding that SB transposase spontaneously penetrates mammalian cells and can be delivered with transposon DNA to gene-modify various cell lines, embryonic, hematopoietic and induced pluripotent stem cells. The invention provides methods and compounds to apply the cell penetrating function of transposase in methods of genetically engineering cells as well as using the transposase as a shuttle for delivering cargo into a target cell or even into a target cell organelle. Genomic integration frequency can be titrated using the technology of the invention, which adds an additional layer of safety, opening opportunities for advanced applications in genetic engineering and gene therapy.

Abstract: The invention concerns a compound characterised by a mono(2-hydroxyethyl) terephthalic acid (MHET) and bis(2-hydroxyethyl) terephthalic acid chemically bonded to a saccharide. Furthermore, the invention concerns a corresponding compound which is used as a synthesis component for polymers or fine chemicals.

Abstract: The present invention relates to methods for predicting the probability of a treatment response of a human cancer patient to an immune checkpoint blocker treatment e.g. with anti PD-1, and to methods for predicting the probability of survival of a human cancer patient following an immune checkpoint blocker treatment, and to apparatuses and kits which can be used in these methods.

Abstract: The present invention relates to a gas delivery device comprising a gas releasing molecule and a gas permeable membrane. The invention also relates to the use of the gas delivery device for delivery of gas to an extracorporeal transplant, extracorporeal cells, a brain-dead transplant donor or foodstuff and in therapy. The invention further relates to the use of a gas permeable and liquid and solid impermeable membrane to separate a gas releasing molecule and its non-gaseous degradation products from an extracorporeal transplant, extracorporeal cells, a brain-dead transplant donor or foodstuff.

Abstract: Methods for treating, reducing or reversing a motor deficit in a subject after a stroke comprising administering continuous electrical stimulation to the mesencephalic locomotor region (MLR) of the subject under sufficient conditions so as to treat, reduce or reverse the motor deficit of the subject are provided.